Abstract:Amyloid- β peptides (Aβ) participate in the development of Alzheimer's disease (AD). AD brains accumulate multiple forms of Aβ peptides, composed of Aβ(1–40/42) with pyroglutamate-Aβ(3–40/42) (pGlu-A β) present as a major portion of Aβ. Several studies estimate that pGlu-A β comprises approximately 50% or more of total A β (Saido et al., 1995; Kuo et al., 1997). The pGlu-Aβ(3–40/42) is hypothesized to facilitate the oligomerization of Aβ(1–40/42) (Schilling et al., 2006) to result in neurotoxicity. The formation of pGlu-Aβ(3–40/42) is produced from the substrate Aβ(3–40/42), which may be generated by a beta-secretase-dependent or -independent mechanism. Cathepsin B has been shown to generate A β(1–40/42) from AD mice expressing APP with the wild-type beta-secretase site (Kindy et al., 2012) expressed in the majority of AD patients. This study, therefore, addresses the role of cathepsin B, possessing wild-type beta-secretase function, in producing pGlu-Aβ(3–40/42). Knockout of the cathepsin B gene was conducted in the APP/Lon mouse model of AD. The APP/Lon mice were also treated with E64d, inhibitor of cathepsin B, by oral administration. Brains were then assessed for levels of pGlu-Aβ(3–40/42) and Aβ(1–40/42), amyloid plaque; animals were evaluated for memory function by the Morris water maze test. Knockout of the cathepsin B gene in the APP/Lon AD mouse model, expressing APP with the wild-type beta-secretase site, was assessed. Knockout of the cathepsin gene resulted in a significant reduction in brain pGlu-Aβ(3–40/42) as well as Aβ(1–40/42). Chemical inhibition of cathepsin B, conducted by oral administration of the E64d inhibitor, in the APP/Lon mice reduced brain pGlu-Aβ(3–40/42) and Aβ(1–40/42). Also, cathepsin B inhibition and gene knockout reduced brain amyloid plaque accumulation and improved memory function in the APP/Lon mice. Cellular studies show that pGlu-Aβ(3–40) is secreted from the regulated secretory pathway of neuronal-like chromaffin cells, and inhibition of cathepsin B (with CA074Me) reduces pGlu-A β(3–40). Results from knockout of the cathepsin B gene in the APP/Lon AD mouse model show that cathepsin B participates in the production of pGlu-Aβ(3–40/42), as well as A β(1–40/42). Cathepsin B inhibitors will likely be effective at reducing neurotoxic pGlu-Aβ(3–40/42), as well as Aβ(1–40/42), for improvement of memory function in AD.

Prominent tauopathy and intracellular β-amyloid accumulation triggered by genetic deletion of cathepsin D: implications for Alzheimer disease pathogenesis

Novel Cathepsin D Inhibitors Block the Formation of Hyperphosphorylated Tau Fragments in Hippocampus

Defects in the autophagy lysosomal pathway in a cell model of disease‐associated tau

Haplodeficiency Of Cathepsin D Does Not Affect Cerebral Amyloidosis And Autophagy In App/Ps1 Transgenic Mice

Broadening Horizons: Exploring the Cathepsin Family as Therapeutic Targets for Alzheimer's Disease

Negative Regulation of Cathepsins by {beta}-Amyloid

Antiamyloidogenic and Neuroprotective Functions of Cathepsin B: Implications for Alzheimer's Disease

A Tauopathy-Homing and Autophagy-Activating Nanoassembly for Specific Clearance of Pathogenic Tau in Alzheimer's Disease.

Cathepsin B Degrades Amyloid-β in Mice Expressing Wild-type Human Amyloid Precursor Protein

Cathepsin D Deficiency Delays Central Nervous System Myelination by Inhibiting Proteolipid Protein Trafficking from Late Endosome/lysosome to Plasma Membrane

Cathepsin in Alzheimer's Disease, Parkinson's Disease and Dementia with Lewy Bodies: Mendelian Randomization Study

Deletion of the Cathepsin B Gene Improves Memory Deficits in a Transgenic ALZHeimer's Disease Mouse Model Expressing AβPP Containing the Wild-Type Β-Secretase Site Sequence.

Cathepsin B modulates microglial migration and phagocytosis of amyloid β in Alzheimer's disease through PI3K-Akt signaling

Spatiotemporal Activation Of The C/Ebp Beta/Delta-Secretase Axis Regulates The Pathogenesis Of Alzheimer'S Disease

Regulatory role of cathepsin L in induction of nuclear laminopathy in Alzheimer’s disease

O1–08–02: Cathepsin B Produces Brain Pyro‐glu‐beta‐amyloid in a Transgenic Alzheimer's Disease Mouse Model

Cathepsin B Modulates Microglial Migration and Phagocytosis of Amyloid Β in Alzheimer’s Disease Through PI3K-Akt Signaling

Blood Cathepsins on the Risk of Alzheimer’s Disease and Related Pathological Biomarkers: Results from Observational Cohort and Mendelian Randomization Study

Autophagy-lysosomal pathway impairment and cathepsin dysregulation in Alzheimer's disease

P2‐359: Cathepsin B Gene Deletion or Inhibition Improves Memory Deficits in a Mouse Model of Alzheimer's Disease Expressing APP with the Wild‐type Beta‐secretase Site

Cathepsin D overexpression in the nervous system rescues lethality and A β 42 accumulation of cathepsin D systemic knockout in vivo